Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The post-COVID-19 recovery period is characterized by persistence of some symptoms, with immunological alterations being of great importance. Development of preventive measures to normalize mucosal immunity after a coronavirus infection determines the relevance of the current study. The aim. To study dynamics of clinical symptoms and level of secretory immunoglobulin A in individuals after a novel coronavirus infection as well as evaluate effectiveness of using interferon alpha-2b. Materials and methods. A study was conducted with patients aged 18 to 60 years old (n=130), surveyed 1 to 9 months after post-infection, as well as in apparently healthy individuals lacking COVID-19 (n=15). Previous novel coronavirus infection and post-COVID manifestations were verified based on medical documentation, complaints, anamnesis data, physical examination and questionnaires. The concentration of salivatory and nasopharyngeal mucosal sIgA was measured dynamically prior to and after administration of local therapy with interferon alpha-2b (gel applied intranasally twice a day for 30 days). Results. The acute period of COVID-19 was characterized by fever, anosmia, fatigue and weakness, muscle and joint pain. Among the post-COVID manifestations at early period (1-3 months), pain in the joints and muscles (75,0%) as well as elevated body temperature (21,2%) were reliably detected, whereas in the long period (6-9 months) there were revealed dominance with the same frequency of shortness of breath, muscle and joint pain (75,8%, respectively). Based on examination data in healthy subjects, there was determined an arbitrary normal range of secretory IgA in saliva 6.451.81 mg/ml and nasal swabs 13.433.24 mg/ml. In the group of patients 1-3 months post-infection, therapy with interferon alfa-2b one month later resulted in significantly increased level of secretory IgA in saliva (from 1.840.28 to 5.781.96 mg/ml) and in nasal swabs (from 28.613.0 to 39.833.85 mg/ml) by more than 3- and 1.5-fold, respectively. In the group of patients without therapy was featured with stably sustained decline in sIgA level up to 9 months after COVID-19. In particular, the level of saliva sIgA ranged from 2.360.56 down to 2.160.66 mg/ml, and in nasal smears from 15.661.32 to 10.231.07 mg/ml that differed insignificantly compared to baseline level. The rate of respiratory diseases prevailed in this group (27.6% of cases), which fully lacked in the group of topically administered interferon alpha-2b. Conclusion. In the post-COVID period, multiple organ disorders persist and reduced sIgA level is registered. Intranasally applied interferon alfa-2b made possible to normalize sIgA level and prevent accumulation of respiratory infectious pathologies.
The post-COVID-19 recovery period is characterized by persistence of some symptoms, with immunological alterations being of great importance. Development of preventive measures to normalize mucosal immunity after a coronavirus infection determines the relevance of the current study. The aim. To study dynamics of clinical symptoms and level of secretory immunoglobulin A in individuals after a novel coronavirus infection as well as evaluate effectiveness of using interferon alpha-2b. Materials and methods. A study was conducted with patients aged 18 to 60 years old (n=130), surveyed 1 to 9 months after post-infection, as well as in apparently healthy individuals lacking COVID-19 (n=15). Previous novel coronavirus infection and post-COVID manifestations were verified based on medical documentation, complaints, anamnesis data, physical examination and questionnaires. The concentration of salivatory and nasopharyngeal mucosal sIgA was measured dynamically prior to and after administration of local therapy with interferon alpha-2b (gel applied intranasally twice a day for 30 days). Results. The acute period of COVID-19 was characterized by fever, anosmia, fatigue and weakness, muscle and joint pain. Among the post-COVID manifestations at early period (1-3 months), pain in the joints and muscles (75,0%) as well as elevated body temperature (21,2%) were reliably detected, whereas in the long period (6-9 months) there were revealed dominance with the same frequency of shortness of breath, muscle and joint pain (75,8%, respectively). Based on examination data in healthy subjects, there was determined an arbitrary normal range of secretory IgA in saliva 6.451.81 mg/ml and nasal swabs 13.433.24 mg/ml. In the group of patients 1-3 months post-infection, therapy with interferon alfa-2b one month later resulted in significantly increased level of secretory IgA in saliva (from 1.840.28 to 5.781.96 mg/ml) and in nasal swabs (from 28.613.0 to 39.833.85 mg/ml) by more than 3- and 1.5-fold, respectively. In the group of patients without therapy was featured with stably sustained decline in sIgA level up to 9 months after COVID-19. In particular, the level of saliva sIgA ranged from 2.360.56 down to 2.160.66 mg/ml, and in nasal smears from 15.661.32 to 10.231.07 mg/ml that differed insignificantly compared to baseline level. The rate of respiratory diseases prevailed in this group (27.6% of cases), which fully lacked in the group of topically administered interferon alpha-2b. Conclusion. In the post-COVID period, multiple organ disorders persist and reduced sIgA level is registered. Intranasally applied interferon alfa-2b made possible to normalize sIgA level and prevent accumulation of respiratory infectious pathologies.
Introduction. The study of the set of mechanisms of inflammation regulation plays an important role in shaping understanding of the local and general protective and adaptive processes in paediatric respiratory infections. The cytokine system is taken as universal, pleiotropic regulators of the cascade of inflammatory, immune and metabolic processes. Nowadays, the drugs with the potential for effecting the course of cytokine reactions are of great interest.Aim. To evaluate the efficacy of the impact of low molecular weight interferon inducers with a wide range of biological activity on the severity of clinical symptoms and the level of pro- and anti-inflammatory cytokines of peripheral blood in paediatric respiratory infections.Materials and methods. 98 children with ARVI aged 4 to 11 years were examined, of which 57 children received meglumine acridone acetate as etiotropic antiviral therapy at recommended age-related doses and were included in the treatment group. 41 children receiving only symptomatic treatment were included in the comparison group.Results and discussions. Clinically, the use of meglumine acridone acetate resulted in decreased duration of the major symptoms of acute viral respiratory infections among children, reduced risk of complications, and decreased inflammatory manifestations. It was shown that the minimum levels of interleukin-1, -4 and -8 were typical for healthy children, which confirmed the activation of cytokine reactions only in the process of development of pathological symptoms from various organs and systems. An increase in all the studied cytokine levels was observed in ARVI, while the dominance in growth of pro-inflammatory cytokines with underlying slightly increased level of anti-inflammatory interleukin-4 was observed in severe general toxic syndrome and catarrhal signs. In similar cases, a balanced decrease in the levels of anti- and pro-inflammatory cytokines and a relatively rapid regression of clinical symptoms was noted during the meglumine acridone acetate therapy.Conclusions. The use of meglumine acridone acetate contributes to the rapid relief of the major clinical symptoms of acute respiratory viral infections, and shortens the duration of the disease. The nature of cytokine reactions can serve as a marker of an unfavourable course of ARVI. The prescription of low-molecular interferon inducers balances an increase in the levels of pro- and anti-inflammatory cytokines of peripheral blood.
Introduction: The role of mitochondria in post coronavirus disease 2019 (post-COVID-19) complications is unclear, especially in the long-term pulmonary complications. This study aims to investigate the association between post-COVID-19 pulmonary complications and mitochondrial regulatory proteins in the context of oxidative stress. Methodology: Patients who had recovered from COVID-19 were enrolled. According to the evidence of persistent interstitial lung lesions on computed tomography (CT), patients were divided into a long-term pulmonary complications group (P(+)) and a control group without long-term pulmonary complications (P(−)). We randomly selected 80 patients for investigation (40 subjects for each group). Biomarkers levels were determined by enzyme-linked immunosorbent assay (ELISA). Results: The serum concentrations of mitochondrial regulatory proteins were significantly higher in the P(+) group, including PTEN-induced kinase 1 (PINK1): 1.62 [1.02–2.29] ng/mL vs. 1.34 [0.94–1.74] ng/mL (p = 0.046); Dynamin-1-like protein (DNM1L): 1.6 [0.9–2.4] ng/mL IQR vs. 0.9 [0.5–1.6] ng/mL (p = 0.004); and Mitofusin-2 (MFN2): 0.3 [0.2–0.5] ng/mL vs. 0.2 [0.1–0.3] ng/mL IQR (p = 0.001). Patients from the P(+) group also had higher serum levels of chemokine ligand 18 (PARC, CCL18), IL-6, and tumour necrosis factor-alpha (TNF-α) cytokines than the P(−) group. The concentration of interferon alpha (IFN-α) was decreased in the P(+) group. Furthermore, we observed statistically significant correlations between the advanced glycation end product (sRAGE) and TNF-α (Pearson’s factor R = 0.637; p < 0.001) and between serum levels of DNM1L and IFN-α (Pearson’s factor R = 0.501; p = 0.002) in P(+) patients. Conclusions: Elevated concentrations of mitochondrial biomarkers in post-COVID-19 patients with long-term pulmonary complications indicate their possible role in the pathobiology of COVID-19 pulmonary sequelae. Oxidative stress is associated with the immune response and inflammation after COVID-19. TNF-α could be a promising biomarker for predicting pulmonary complications and may be a potential target for therapeutic intervention in patients with post-COVID-19 complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.